Kanada - anglų - Health Canada

mylan pharmaceuticals ulc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Kanada - anglų - Health Canada

juno pharmaceuticals corp. - ipratropium bromide (ipratropium bromide monohydrate); salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide (ipratropium bromide monohydrate) 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v - solution for inhalation - 250 mcg/ml - active: ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v excipient: hydrochloric acid sodium chloride water for injection - ipratropium bromide is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema and when used concomitantly with inhaled beta-agonists, for asthma.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v - solution for inhalation - 0.5 mg/2ml - active: ipratropium bromide monohydrate 0.0261%{relative} equivalent to ipratropium 0.025% w/v excipient: hydrochloric acid sodium chloride water for injection - ipratropium bromide is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema and when used concomitantly with inhaled beta-agonists, for asthma.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

cipla usa inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - albuterol 2.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 20 ug - combivent respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (copd) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. combivent respimat is contraindicated in the following conditions [see warnings and precautions (5.6) ]: - hypersensitivity to any of the ingredients in combivent respimat - hypersensitivity to atropine or any of its derivatives risk summary there are no randomized clinical studies of combivent respimat, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . published literature, including cohort studies, case control studies and case series, over s

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide 21 ug - atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. atrovent® (ipratropium bromide) nasal spray 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. atrovent® (ipratropium bromide) nasal spray 0.03% 21 mcg/spray read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip asso

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ritedose pharmaceuticals, llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - albuterol 2.5 mg in 3 ml - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration